Salivary gland toxicity of PSMA radioligand therapy: relevance and preventive strategies
T Langbein, G Chaussé, RP Baum - Journal of Nuclear Medicine, 2018 - Soc Nuclear Med
Since the first clinical use of 131I-labeled prostate-specific membrane antigen (PSMA)(1),
xerostomia has been identified as a relevant side effect of PSMA radioligand therapies (PRLTs…
xerostomia has been identified as a relevant side effect of PSMA radioligand therapies (PRLTs…
Blinded clinical evaluation for dementia of Alzheimer's type classification using FDG-PET: A comparison between feature-engineered and non-feature-engineered …
…, LM Jenkins, K Popuri, G Chausse… - Journal of …, 2021 - content.iospress.com
Background: Advanced machine learning methods can aid in the identification of dementia
risk using neuroimaging-derived features including FDG-PET. However, to enable the …
risk using neuroimaging-derived features including FDG-PET. However, to enable the …
Comparing digital to analog prostate-specific membrane antigen-targeted piflufolastat 18F PET/CT in prostate cancer patients in early biochemical failure
…, A Ebrahim, G Abikhzer, G Chaussé… - Nuclear Medicine …, 2023 - journals.lww.com
Purpose Prostate-specific membrane antigen (PSMA) positron emission tomography/computer
tomography (PET/CT) in prostate cancer patients with biochemical failure (BCF) …
tomography (PET/CT) in prostate cancer patients with biochemical failure (BCF) …
[HTML][HTML] 18F-fluorocholine positron emission tomography-computed tomography (18F-FCH PET/CT) for staging of high-risk prostate cancer patients
S Gauvin, A Rompré-Brodeur, G Chaussé… - Canadian Urological …, 2019 - ncbi.nlm.nih.gov
Methods We conducted a retrospective study of 76 patients who underwent 18 F-FCH PET/CT
for initial staging of high-risk prostate cancer. Using pre-established validation criteria, …
for initial staging of high-risk prostate cancer. Using pre-established validation criteria, …
[HTML][HTML] Diagnostic performance of 18F-DCFPyL positron emission tomography/computed tomography for biochemically recurrent prostate cancer and change-of …
G Chaussé, N Ben-Ezra, M Stoopler… - Canadian Urological …, 2021 - ncbi.nlm.nih.gov
Methods Ninety-three 18 F-DCFPyL PET/CT scans performed for patients previously treated
for prostate cancer with a rising prostate-specific antigen (PSA) were retrospectively …
for prostate cancer with a rising prostate-specific antigen (PSA) were retrospectively …
Splenic hemangioma as a potential pitfall on PSMA-targeted 18F-DCFPyL PET/CT
G Chaussé, J Laufer, G Abikhzer… - Clinical Nuclear …, 2019 - journals.lww.com
A 69-year-old man with biochemical recurrence after radical prostatectomy underwent 6 months
of androgen deprivation therapy. Upon discontinuation of androgen deprivation therapy, …
of androgen deprivation therapy. Upon discontinuation of androgen deprivation therapy, …
[HTML][HTML] Temperament and character personality dimensions in nitrate-tilt-induced vasovagal syncope patients
…, A AlTurki, A Rago, R Proietti, G Chaussé… - Hellenic Journal of …, 2017 - Elsevier
Objective Vasovagal syncope (VVS) is a clinical syndrome that is characterized by a transient
loss of consciousness and postural tone that are due to a temporary, spontaneously self-…
loss of consciousness and postural tone that are due to a temporary, spontaneously self-…
PSMA‐Hornet: Fully‐automated, multi‐target segmentation of healthy organs in PSMA PET/CT images
IS Klyuzhin, G Chaussé, I Bloise, S Harsini… - Medical …, 2024 - Wiley Online Library
Background Prostate‐specific membrane antigen (PSMA) PET imaging represents a valuable
source of information reflecting disease stage, response rate, and treatment optimization …
source of information reflecting disease stage, response rate, and treatment optimization …
Automated deep segmentation of healthy organs in PSMA PET/CT images
1410 Objectives: As PET imaging of prostate-specific membrane antigen (PSMA) becomes
more widely-adopted following FDA approval, the role of healthy organ segmentation with …
more widely-adopted following FDA approval, the role of healthy organ segmentation with …
Ureteral metastasis from prostate cancer: a PSMA PET pitfall
G Chaussé, B Skinnider, J Crook, P Black… - Clinical Nuclear …, 2020 - journals.lww.com
A 72-year-old man with a history of prostate adenocarcinoma initially managed by radical
prostatectomy and salvage radiation therapy underwent resection of a left vas deferens …
prostatectomy and salvage radiation therapy underwent resection of a left vas deferens …